Key result
Baseline macroscale EEG characteristics did not significantly differ between antipsychotic-naïve patients with first-episode psychosis and healthy controls, but explained 23% of the variance in positive symptom reduction following 4-6 weeks of antipsychotic treatment.
Why the study?
EEG findings in first-episode psychosis have varied due to small sample sizes, medication effects, and variable illness duration, leaving its utility for diagnosis and treatment prediction uncertain.
Can macroscale resting-state EEG characteristics differentiate antipsychotic-naïve first-episode psychosis patients from healthy controls and predict treatment response?
Observational (n=168)
Yes
Can macroscale resting-state EEG characteristics differentiate antipsychotic-naïve first-episode psychosis patients from healthy controls and predict treatment response?
Effect estimate: R² 0.23
p-value: p=0.004
While macroscale EEG characteristics do not differentiate antipsychotic-naïve first-episode psychosis patients from healthy controls, they may have predictive value for positive symptom reduction following antipsychotic treatment.
Electroencephalography in patients with a first episode of psychosis (FEP) may contribute to the diagnosis and treatment response prediction. Findings in the literature vary due to small sample sizes, medication effects, and variable illness duration. We studied macroscale resting-state EEG characteristics of antipsychotic naïve patients with FEP. We tested (1) for differences between FEP patients and controls, (2) if EEG could be used to classify patients as FEP, and (3) if EEG could be used to predict treatment response to antipsychotic medication. In total, we studied EEG recordings of 62 antipsychotic-naïve patients with FEP and 106 healthy controls. Spectral power, phase-based and amplitude-based functional connectivity, and macroscale network characteristics were analyzed, resulting in 60 EEG variables across four frequency bands. Positive and Negative Symptom Scale (PANSS) were assessed at baseline and 4-6 weeks follow-up after treatment with amisulpride or aripiprazole. Mann-Whitney U tests, a random forest (RF) classifier and RF regression were used for statistical analysis. Our study found that at baseline, FEP patients did not differ from controls in any of the EEG characteristics. A random forest classifier showed chance-level discrimination between patients and controls. The random forest regression explained 23% variance in positive symptom reduction after treatment in the patient group. In conclusion, in this largest antipsychotic- naïve EEG sample to date in FEP patients, we found no differences in macroscale EEG characteristics between patients with FEP and healthy controls. However, these EEG characteristics did show predictive value for positive symptom reduction following treatment with antipsychotic medication.
No takes yet. Share an insight, caveat, or question.
Dominicus et al. (2023) conducted an observational in First-episode psychosis (n=168). Baseline macroscale EEG characteristics vs. Healthy controls was evaluated on Variance in positive symptom reduction (ΔPANSS positive) at 4-6 weeks (R² 0.23, p=0.004). Baseline macroscale EEG characteristics did not significantly differ between antipsychotic-naïve patients with first-episode psychosis and healthy controls, but explained 23% of the variance in positive symptom reduction following 4-6 weeks of antipsychotic treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: